07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

Byron Biopharma, Cel-Sci deal

Cel-Sci granted Byron exclusive rights to commercialize Multikine in South Africa. Byron paid Cel-Sci a $125,000 licensing fee and will be responsible for obtaining regulatory approval in the territory. Cel-Sci will manufacture the product, and...